Allergan Acular PF
"Fast relief" claim in promotional materials submitted by Allergan are without context, so company must discontinue use of brochure and any other materials that make claim, FDA says in July 23 letter. The brochure urges physicians to "prescribe Acular PF for fast relief from ocular pain and photophobia following incisional refractive surgery," FDA says. The letter was sent to Roche, which acquired the Acular (ketorolac ophthalmic solution) NDA when it bought Syntex. Allergan markets the product
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth